On Nov. 17, 2020, Moderna announced a supply agreement with the government of the United Kingdom (UK) to supply mRNA-1273, its COVID-19 vaccine candidate, beginning in March 2021 if approved for use by UK regulatory authorities. This agreement comes as the UK continued its efforts to secure access to safe and effective COVID-19 vaccines.

On October 27, 2020, Moderna received confirmation that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom started the rolling review process of mRNA-1273. The investments in this proprietary platform enabled Moderna to expeditiously create, manufacture and clinically develop mRNA-1273 in support of the global response to the current COVID-19 pandemic. Moderna continued to scale up its global manufacturing to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year, beginning in 2021. T

The Company was working with its strategic manufacturing partners, Lonza of Switzerland and ROVI of Spain, for manufacturing and fill-finish outside of the United States. This was a dedicated supply chain to support Europe and countries other than the United States that entered into purchase agreements with Moderna.